ADDING QUALITY YEARS TO LIFE

We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in these patients.

ABOUT US

Our focus

Priothera is leading the way in developing orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies.

S1P receptor modulators have shown to largely reduce the egress of T-cell subsets from lymphatic tissues and are thereby suggested to inhibit graft-versus-host disease (GvHD)  while at the same time enhancing graft-versus-leukemia benefits in patients receiving allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Priothera is developing mocravimod (KRP-203), a S1P receptor modulator (S1PR), to enhance the curative potential of allogeneic HSCT. Mocravimod, acquired from KYORIN Pharmaceutical has been extensively tested in multiple immunological models and has shown a survival benefit and reduced severity of GvHD in a clinical study evaluating acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients undergoing allogeneic HSCT.

Our Clinical Candidate

Hematopoietic Stem Cell Transplantation (HSCT)

Our Pipeline

About AML

Acute myeloid leukemia (AML) is an aggressive and highly proliferative form of cancer where the bone marrow generates abnormal myeloblasts (a type of white blood cell).

Acute myeloid leukemia (AML) is an aggressive and highly proliferative form of cancer where the bone marrow generates abnormal myeloblasts (a type of white blood cell).

AML is the most common form of leukemia in adults and progresses quickly if left untreated, typically leading to death within a few months of diagnosis. Various chemotherapy regimens followed by allogeneic hematopoietic stem cell transplantation (HSCT) in cases associated with the most severe prognosis have improved disease free survival.

More recently, the use of genetic testing in combination with a number of targeted therapies has transformed treatment of AML for a large subset of patients.

In parallel, a better understanding of the role of the immune system in AML has added immune modulators to chemotherapy and allogeneic HSCT as new treatment modalities.

However, a strong unmet need remains to improve patient outcomes by rebalancing the immune system to prevent relapse and transplant-related toxicities including graft-versus-host disease (GvHD).

Despite progress in reducing transplant-related mortality, no major clinical improvements of post-transplant relapse incidence or significantly improved overall survival have been achieved over the last four decades.

The impact of acute Myeloid Leukemia

New estimated cases of leukemia (all kinds) in the US in 2020

New estimated cases of acute myeloid leukemia (AML) in the US in 2020

Estimated deaths from AML in the US in 2020

*From the American Cancer Society – Estimates for leukemia in the US for 2020

CEO & Director Statement

“Mocravimod has a unique mechanism of action and clinical proof of concept demonstrating its ability to improve survival outcomes for this devastating disease.”

Florent Gros – Founder, CEO

“Mocravimod is an outstanding, well-characterized and well-behaved S1P receptor modulator that is well-suited for clinical development and commercial manufacturing. Mocravimod has the potential to be a best-in-class therapy to ameliorate the morbidity and mortality associated with HSCT for AML.”

Dhaval Patel – Fouders, director, led Research Europe and the Autoimmunity, Transplantation and Inflammation Disease Area at Novartis

Our partnership

Priothera has acquired Mocravimod (KRP203) from Japanese Pharmaceutical company KYORIN Pharmaceutical, with KYORIN retaining certain rights in Japan and South Korea.

Contact Us

Priothera Ltd
88 Harcourt Street, Dublin 2, D02 DK18, Ireland

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland

Priothera SAS France
9 Rue du Temple, Saint Louis, 68300, France